MARKET

MRNS

MRNS

Marinus Pharmace
NASDAQ
6.94
+0.19
+2.81%
Closed 16:00 10/04 EDT
OPEN
6.90
PREV CLOSE
6.75
HIGH
7.07
LOW
6.81
VOLUME
112.49K
TURNOVER
620.42K
52 WEEK HIGH
13.15
52 WEEK LOW
3.970
MARKET CAP
258.16M
P/E (TTM)
-2.4044
1D
5D
1M
3M
1Y
5Y
BARDA Exercises First Contract Option With Marinus Pharma For Its Epilepsy Candidate
Benzinga · 09/22 14:55
US government uses contract option for Marinus' seizure therapy ganaxolone
Marinus Pharmaceuticals (NASDAQ:MRNS) <a href="https://se...
Seekingalpha · 09/22 12:31
Marinus Pharmaceuticals Announces Exercise Of First Contract Option By Biomedical Advanced Research And Development Authority
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research and Development
Benzinga · 09/22 11:31
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa., September 09, 2022--Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · 09/09 20:05
Marinus Pharmaceuticals (NASDAQ:MRNS) shareholders have endured a 59% loss from investing in the stock five years ago
While it may not be enough for some shareholders, we think it is good to see the Marinus Pharmaceuticals, Inc...
Simply Wall St. · 09/08 13:03
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
RADNOR, Pa., September 07, 2022--Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire · 09/07 11:30
Looking Into Marinus Pharmaceuticals's Return On Capital Employed
Marinus Pharmaceuticals (NASDAQ:MRNS) brought in sales totaling $1.79 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 103.67%, resulting in a loss of $39.43 million.
Benzinga · 09/06 14:04
Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Marinus Pharmaceuticals (NASDAQ:MRNS) on Monday <a ...
Seekingalpha · 08/29 20:16
More
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company, which is focused on the development of therapeutics for seizure disorders. The Company's commercial product, ZTALMY (ganaxolone) oral suspension CV for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. The Company’s ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.